TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.02 CNY | +3.15% |
|
+8.20% | +3.84% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 5,707 | 7,559 | 11,197 | 8,633 | 7,574 | 7,873 | - | - |
| Enterprise Value (EV) 1 | 5,707 | 7,559 | 11,197 | 9,125 | 8,102 | 8,694 | 8,747 | 8,045 |
| P/E ratio | 29.5 x | 18.8 x | 23.5 x | 24.9 x | 16.8 x | 14.5 x | 12.4 x | 10.1 x |
| Yield | 1.73% | 2.12% | 1.45% | 1.61% | 2.44% | 2.53% | 3.08% | 3.67% |
| Capitalization / Revenue | 3.89 x | 3.78 x | 5.58 x | 4.14 x | 3.37 x | 2.85 x | 2.42 x | 2.1 x |
| EV / Revenue | 3.89 x | 3.78 x | 5.58 x | 4.38 x | 3.6 x | 3.15 x | 2.69 x | 2.15 x |
| EV / EBITDA | 16.1 x | 12.4 x | 19.2 x | 17.4 x | 11.5 x | 11.6 x | 9.82 x | 7.78 x |
| EV / FCF | - | - | - | - | 27.6 x | -20.9 x | 67.8 x | - |
| FCF Yield | - | - | - | - | 3.62% | -4.77% | 1.47% | - |
| Price to Book | 2.75 x | 3.11 x | 2.41 x | 2.06 x | 1.7 x | 1.58 x | 1.46 x | 1.31 x |
| Nbr of stocks (in thousands) | 394,965 | 400,356 | 464,207 | 463,881 | 462,139 | 462,587 | - | - |
| Reference price 2 | 14.45 | 18.88 | 24.12 | 18.61 | 16.39 | 16.50 | 16.50 | 16.50 |
| Announcement Date | 20-02-25 | 21-03-01 | 22-03-25 | 23-03-31 | 24-03-29 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,467 | 2,000 | 2,007 | 2,084 | 2,249 | 2,761 | 3,255 | 3,742 |
| EBITDA 1 | 355.6 | 609.7 | 583.7 | 524.7 | 704.2 | 750.6 | 890.4 | 1,034 |
| EBIT 1 | 263.1 | 513.1 | 499.4 | 416.6 | 565.2 | 619.7 | 726.6 | 877.5 |
| Operating Margin | 17.94% | 25.65% | 24.88% | 19.99% | 25.13% | 22.45% | 22.32% | 23.45% |
| Earnings before Tax (EBT) 1 | 259.9 | 510.9 | 487.8 | 413.8 | 566.7 | 631 | 737.1 | 907.9 |
| Net income 1 | 194.4 | 398.2 | 412.8 | 346.7 | 452.9 | 529.8 | 619.7 | 763.8 |
| Net margin | 13.25% | 19.91% | 20.57% | 16.63% | 20.14% | 19.19% | 19.04% | 20.41% |
| EPS 2 | 0.4894 | 1.006 | 1.026 | 0.7488 | 0.9772 | 1.136 | 1.329 | 1.638 |
| Free Cash Flow 1 | - | - | - | - | 293.4 | -415 | 129 | - |
| FCF margin | - | - | - | - | 13.05% | -15.03% | 3.96% | - |
| FCF Conversion (EBITDA) | - | - | - | - | 41.67% | - | 14.49% | - |
| FCF Conversion (Net income) | - | - | - | - | 64.79% | - | 20.82% | - |
| Dividend per Share 2 | 0.2500 | 0.4000 | 0.3500 | 0.3000 | 0.4000 | 0.4174 | 0.5084 | 0.6050 |
| Announcement Date | 20-02-25 | 21-03-01 | 22-03-25 | 23-03-31 | 24-03-29 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 S1 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 S2 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2024 S2 | 2025 Q1 | 2025 Q2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | 908.3 | - | 607.5 | 1,176 | - | - | 593.1 | 1,255 | - | 1,279 | - | - | 1,411 | - | - | 1,571 | 1,571 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | 168.8 | - | 132 | 247.9 | - | - | 110.8 | 349.3 | - | 236.7 | - | - | 282 | - | - | 312.4 | 311.5 |
| Operating Margin | 18.58% | - | 21.72% | 21.08% | - | - | 18.69% | 27.84% | - | 18.5% | - | - | 19.99% | - | - | 19.89% | 19.83% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | 93.19 | - | - | - | 97.45 | 95.43 | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | 16.09% | - | - | - | - | - | - | - | - | - | - |
| EPS | - | 0.2009 | 0.2500 | - | 0.1742 | 0.2100 | 0.2100 | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share 1 | - | - | 0.3000 | - | - | - | - | - | - | - | - | 0.4598 | - | - | - | - | - |
| Announcement Date | 22-08-25 | 22-10-25 | 23-03-31 | 23-03-31 | 23-04-26 | 23-08-25 | 23-10-25 | 24-03-29 | - | - | - | - | - | - | - | - | - |
1CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 492 | 528 | 820 | 874 | 172 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | 0.9383 x | 0.7495 x | 1.093 x | 0.9812 x | 0.1664 x |
| Free Cash Flow 1 | - | - | - | - | 293 | -415 | 129 | - |
| ROE (net income / shareholders' equity) | 9.41% | 17.5% | 12.7% | 8.41% | 10.4% | 11% | 11.7% | 12.8% |
| ROA (Net income/ Total Assets) | 5.92% | 10.7% | 8.61% | 5.88% | - | 7.75% | 8.42% | 9.15% |
| Assets 1 | 3,281 | 3,731 | 4,795 | 5,899 | - | 6,836 | 7,365 | 8,348 |
| Book Value Per Share 2 | 5.250 | 6.070 | 10.00 | 9.020 | 9.640 | 10.50 | 11.30 | 12.60 |
| Cash Flow per Share 2 | 0.9500 | 0.9600 | 0.9500 | 0.8300 | 0.8100 | 0.9900 | 1.550 | 1.540 |
| Capex 1 | 228 | 259 | 303 | 372 | 84.8 | 275 | 254 | 329 |
| Capex / Sales | 15.57% | 12.95% | 15.08% | 17.86% | 3.77% | 9.94% | 7.8% | 8.79% |
| Announcement Date | 20-02-25 | 21-03-01 | 22-03-25 | 23-03-31 | 24-03-29 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
16.5
CNY
Average target price
21.14
CNY
Spread / Average Target
+28.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.84% | 1.06B | |
| -8.56% | 6.54B | |
| +27.25% | 3.8B | |
| -3.06% | 3.2B | |
| +11.32% | 1.5B | |
| -14.30% | 1.44B | |
| -23.61% | 1.28B | |
| -9.13% | 1.21B | |
| -6.93% | 1.2B | |
| -11.09% | 853M |
- Stock Market
- Equities
- 300119 Stock
- Financials Tianjin Ringpu Bio-Technology Co.,Ltd.